This page shows the latest King Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.
The company secured rights to Troxyca ER (also known as ALO-02) when it acquired King Pharmaceuticals in 2010 for $3.6bn.
The initial development of this immediate-release tamper-resistant formulation, formally known as Acurox, was under collaboration with Acura and King Pharmaceuticals. ... As part of the research programme initiated by King Pharmaceuticals (now Pfizer)
Paul brings more than 15 years experience in managing projects and clients across a wide range of sectors including FMCG and pharmaceuticals. ... His work includes brand delivery for some of the biggest names in the sector, most notably: Adcock Ingram,
Sales were aided by the purchase of King Pharmaceuticals, with Pfizer gaining an extra $357m in sales.
Oxecta was originally developed by King Pharmaceuticals. Pfizer acquired the drug when it purchased King in late 2010.
Marketed products. The M&A strategy in 2010 was reflected in Pfizer's acquisition of King Pharmaceuticals for $3.6bn announced in October and Astellas' acquisition of OSI Pharmaceuticals for $4bn ... Nevertheless there were a few deals in 2010, such as
More from news
Approximately 0 fully matching, plus 21 partially matching documents found.
Dr Sommerville was VP, clinical sciences, at Pfizer for three years having joined the company from King Pharmaceuticals.
He was promoted to senior director of medical affairs and then after King Pharmaceuticals' acquisition of Alpharma, Dr Sun served as King's senior director of pharmacovigilance and risk management.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
We're a leading healthcare strategic communications agency helping pharmaceutical companies adapt fast to improve the lives of patients and healthcare...